Nikkhah G, Tonn J C, Hoffmann O, Kraemer H P, Darling J L, Schachenmayr W, Schönmayr R
Institute of Neuropathology, Giessen, Germany.
J Neurooncol. 1992 May;13(1):13-24. doi: 10.1007/BF00172942.
In this study we assessed the influence of patient- and drug-specific parameters in the short-term MTT-chemosensitivity assay in 150 primary cell cultures derived from human brain tumors. In 45 patients the MTT assay was directly compared with the CFA (Colony Forming Assay). Resistance was 10-20% higher in the MTT assay than in the CFA, but there was a good agreement in both assays, that more malignant gliomas had a higher in vitro chemosensitivity against ACNU and BCNU. Overall the results demonstrate, that there is no uniform correlation between the in vitro chemosensitivity and the histopathological classification of the tumors, which corresponds well to the clinical situation. On the basis of this study we suggest prospective clinical trials with the MTT assay in human brain tumors.
在本研究中，我们评估了患者特异性和药物特异性参数对源自人脑肿瘤的150种原代细胞培养物短期MTT化学敏感性测定的影响。在45例患者中，MTT测定与CFA（集落形成测定）进行了直接比较。MTT测定中的耐药性比CFA高10 - 20%，但两种测定结果具有良好的一致性，即更多恶性胶质瘤对ACNU和BCNU具有更高的体外化学敏感性。总体而言，结果表明，肿瘤的体外化学敏感性与组织病理学分类之间不存在统一的相关性，这与临床情况相符。基于本研究，我们建议对人脑肿瘤进行MTT测定的前瞻性临床试验。
